Provectus Biopharmaceuticals, Inc. Share Price
Equities
PVCT
US74373P1084
Biotechnology & Medical Research
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
0.199 USD | +0.25% | +2.16% | +107.29% |
Sales 2022 | 0.99 78.73 | Sales 2023 | 0.56 44.4 | Capitalization | 40.27M 3.21B |
---|---|---|---|---|---|
Net income 2022 | -3M -239M | Net income 2023 | -3M -239M | EV / Sales 2022 | 48,121,944 x |
Net Debt 2022 | 2.16M 172M | Net Debt 2023 | 2.95M 235M | EV / Sales 2023 | 77,502,175 x |
P/E ratio 2022 |
-12.8
x | P/E ratio 2023 |
-13
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 90.58% |
1 day | +0.25% | ||
1 week | +2.16% | ||
Current month | +8.80% | ||
1 month | +4.68% | ||
3 months | +76.26% | ||
6 months | +160.47% | ||
Current year | +107.29% |
Managers | Title | Age | Since |
---|---|---|---|
Edward Pershing
CEO | Chief Executive Officer | 71 | 26/04/18 |
Eric A. Wachter
FOU | Founder | 61 | 31/12/01 |
Heather Raines
DFI | Director of Finance/CFO | 58 | 31/07/17 |
Members of the board | Title | Age | Since |
---|---|---|---|
Eric A. Wachter
FOU | Founder | 61 | 31/12/01 |
John W. Lacey
BRD | Director/Board Member | 76 | 26/04/18 |
President | 55 | 02/04/17 |
Date | Price | Change | Volume |
---|---|---|---|
29/04/24 | 0.199 | +0.25% | 149 227 |
26/04/24 | 0.1985 | +1.07% | 39,686 |
25/04/24 | 0.1964 | +1.24% | 251,000 |
24/04/24 | 0.194 | -0.41% | 67,734 |
23/04/24 | 0.1948 | 0.00% | 138,051 |
Delayed Quote OTC Markets, April 29, 2024 at 08:55 pm
More quotes1st Jan change | Capi. | |
---|---|---|
+107.29% | 83.28M | |
-2.63% | 103B | |
+1.62% | 95.28B | |
+1.46% | 22.15B | |
-16.67% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.21% | 16.05B | |
+5.41% | 13.68B | |
+33.57% | 12.17B |
- Stock Market
- Equities
- PVCT Stock